THE IDENTIFICATION, purification and development of a radioimmunoassay for a new and apparently unique adrenalseminal-pituitary protein (ASP) has been described (Al-Awqati et al., 1979a,b) . ASP is a protein with a mol. wt of about 25,000 and an electrophoretic mobility in the pre-albumin region. The exact biological function of ASP is unknown, though recent evidence of increased serum levels after oral administration of a prostaglandin synthetase inhibitor (Froben) indicate that it may be associated with prostaglandin physiology (Etheridge et al., in press).
Serum samples from 74 patients (aged 17-81 years) with leukaemia were assayed for ASP. Of these patients, 22 had chronic lymphatic leukaemia (CLL), 15 had acute myeloblastic leukaemia (AML), 15 had acute lymphoblastic leukaemia (ALL), 13 had acute myelomonocytic leukaemia (AMML) and 9 had acute monocytic leukaemia (AMOL).
Serum samples were also obtained from 99 patients with localized breast cancer, 101 patients with disseminated breast cancer and 10 patients with benign breast tumours. The diagnosis and staging of disease (including extra-mammary spread) was based upon conventional clinical, Accepted 8 January 1980 histological and radiological criteria. Serum carcinoembryonic antigen (CEA) levels were available on 83 of these samples.
ASP and CEA levels were measured by radioimmunoassay (Al-Awqati et al., 1979b; Laurence et al., 1972) .
Leukaemia. The results are shown in Fig. 1 . Whilst the mean serum ASP level of patients with leukaemia was 448 Hg/l compared to a mean of 240 Htg/l in normal controls, the most striking elevations were only seen in AMML and AMOL. However, 2 cases of CLL had ASP levels higher than any of the values seen in AMOL.
Breast cancer. The results are shown in Figs 2 and 3. In all patients with benign breast lumps, serum ASP levels were within the normal range (80-450 fkg/l). In contrast, high concentrations of ASP (above the 95th centile of controls) were detected in 23% and 25% of patients with apparently localized and disseminated breast cancer respectively. No true distinction between localized and metastatic breast cancer was seen on the basis of ASP though this could be obtained with CEA (Fig. 3) . There was no correlation between ASP and CEA levels. Only patients with disseminated disease ex- hibited a concordant elevation of both proteins.
ASP is a newly described human protein occurring at very high concentrations in the adrenal and pituitary glands. The fact that high levels of this protein are also found in seminal plasma, together with the observed changes in serum ASP levels after oral ingestion of a prostaglandin synthetase inhibitor (Etheridge et al., in press) suggest that ASP is closely related to some aspect of prostaglandin physiology. For the past few years, prostaglandins have been increasingly implicated in many aspects of tumour development and growth (Editorial Lancet, 1979; Jaffe, 1974) . However, there is no evidence of an association between prostaglandins and breast cancer or leukaemias. The results of this study are of great interest in view of both the general elevation in serum ASP levels and, more important, the striking differences between the various types of leukaemia studied. At the present time, and until more is known about the exact biology of ASP, it is futile to speculate on the relationship between this protein and the neoplastic process; e.g. whether it is a primary product of the tumour cells, or the result of a secondary response to the tumour. Nevertheless, these preliminary observations should prompt further investigations into the pathological significance of raised serum levels of ASP in human neoplasms. 
